%0 Journal Article
%T Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%A Metro, Giulio
%A Di Maio, Massimo
%J Translational Lung Cancer Research
%D 2018
%B 2018
%9 
%! Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
%K 
%X Targeted treatment with a tyrosine kinase inhibitor (TKI) is associated with high response rates and significantly prolonged progression-free survival in the minority of patients (approximately 15–20%) with advanced non-small cell lung cancer (NSCLC) whose tumor harbors an epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) rearrangement or ROS1 rearrangement (1).
%U https://tlcr.amegroups.org/article/view/23047
%P S290-S293
%@ 2226-4477